First Time Loading...
S

Shandong Jincheng Pharmaceutical Group Co Ltd
SZSE:300233

Watchlist Manager
Shandong Jincheng Pharmaceutical Group Co Ltd
SZSE:300233
Watchlist
Price: 19.45 CNY 3.35% Market Closed
Updated: May 6, 2024
Section:
 

Relative Value

The Relative Value of one Shandong Jincheng Pharmaceutical Group Co Ltd stock under the Base Case scenario is 20.31 CNY. Compared to the current market price of 19.45 CNY, Shandong Jincheng Pharmaceutical Group Co Ltd is Undervalued by 4%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
20.31 CNY
Undervaluation 4%
Relative Value
Price
S
Worst Case
Base Case
Best Case

Valuation Multiples

2.1
P/S
P/S
Price to Sales
2.1
vs History
88
vs Industry
53
Median 3Y
2.6
Median 5Y
2.7
Industry
2.5
Forward
1.4
More Details
42.7
P/E
P/E
Price to Earnings
42.7
vs History
31
vs Industry
10
Median 3Y
38.5
Median 5Y
36.5
Industry
23.4
Forward
10.6
More Details
11.2
P/OCF
P/OCF
Price to OCF
11.2
vs History
90
vs Industry
33
Median 3Y
23.5
Median 5Y
17.6
Industry
17.4
More Details
33.4
P/FCFE
P/FCFE
Price to FCFE
33.4
vs History
47
vs Industry
17
Median 3Y
32.9
Median 5Y
32.4
Industry
23.6
More Details
2
P/B
P/B
Price to Book Value
2
vs History
65
vs Industry
41
Median 3Y
2.6
Median 5Y
2.2
Industry
2.1
More Details
2.1
EV/S
EV/S
Enterprise Value to Sales
2.1
vs History
85
vs Industry
52
Median 3Y
2.6
Median 5Y
2.6
Industry
2.6
Forward
1.4
More Details
4.8
EV/GP
EV/GP
Enterprise Value to Gross Profit
4.8
vs History
60
vs Industry
43
Median 3Y
5.4
Median 5Y
5
Industry
5.2
More Details
30.7
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
30.7
vs History
30
vs Industry
11
Median 3Y
25.9
Median 5Y
25.4
Industry
13.7
Forward
7.2
More Details
30.7
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
30.7
vs History
30
vs Industry
14
Median 3Y
25.9
Median 5Y
25.4
Industry
17.2
More Details
11
EV/OCF
EV/OCF
Enterprise Value to OCF
11
vs History
90
vs Industry
36
Median 3Y
22.9
Median 5Y
16.9
Industry
16.2
More Details
22.6
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
22.6
vs History
60
vs Industry
19
Median 3Y
19.3
Median 5Y
29.1
Industry
17.8
More Details
1.6
EV/IC
EV/IC
Enterprise Value to IC
1.6
vs History
87
vs Industry
44
Median 3Y
2.1
Median 5Y
1.9
Industry
2
More Details

Multiples Across Competitors

Competitors Multiples
Shandong Jincheng Pharmaceutical Group Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Shandong Jincheng Pharmaceutical Group Co Ltd
SZSE:300233
7.5B CNY 2.1 42.7 30.7 30.7
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
716.9B USD 20 116.8 57.2 65.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
3.8T DKK 16.4 45.4 33.2 36.2
US
Johnson & Johnson
NYSE:JNJ
356.2B USD 4.2 9.3 11.4 14.9
US
Merck & Co Inc
NYSE:MRK
321.2B USD 5.2 139.3 33.2 52.6
UK
AstraZeneca PLC
LSE:AZN
186.8B GBP 5.1 39.4 140.7 225.7
CH
Novartis AG
SIX:NOVN
180B CHF 4.3 13.4 9.8 16.2
CH
Roche Holding AG
SIX:ROG
174.5B CHF 3 15.2 8.6 10.3
US
Pfizer Inc
NYSE:PFE
158.8B USD 2.9 -513.9 12.8 20.3
P/E Multiple
Earnings Growth
CN
S
Shandong Jincheng Pharmaceutical Group Co Ltd
SZSE:300233
Average P/E: 52.7
42.7
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
116.8
346%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
DK
Novo Nordisk A/S
CSE:NOVO B
45.4
84%
US
Johnson & Johnson
NYSE:JNJ
9.3
-20%
US
Merck & Co Inc
NYSE:MRK
139.3
7 454%
UK
AstraZeneca PLC
LSE:AZN
39.4
168%
CH
Novartis AG
SIX:NOVN
13.4
15%
CH
Roche Holding AG
SIX:ROG
15.2
26%
US
Pfizer Inc
NYSE:PFE
Negative Multiple: -513.9
680%

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 134,800+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.